Study details
Enrolling now
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
LB Pharmaceuticals Inc.
NCT IDNCT07363577ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Ages
18–65
Locations
1 site in CA
What this study is about
This Phase 3 study is focused on people with schizophrenia. The primary outcome being measured is Change from baseline to Week 6 on the Positive and Negative Syndrome Scale.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
OralOral
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug routes
oral
Endpoints
Primary: Change from baseline to Week 6 on the Positive and Negative Syndrome Scale
Secondary: Evaluate the Safety and Tolerability of LB-102
Body systems
Psychiatry / Mental Health